{"title":"Crisaborole and Apremilast: PDE4 Inhibitors with Similar Mechanism of Action, Different Indications for Management of Inflammatory Skin Conditions","authors":"J. Kitzen, J. Pergolizzi, Robert Taylor, R. Raffa","doi":"10.4236/PP.2018.99028","DOIUrl":null,"url":null,"abstract":"Two \nselective phosphodiesterase-4 (PDE4) inhibitors—viz., crisaborole (Eucrisa®, \nPfizer) and apremilast (Otezla®, Celgene)—have recently received approval by the United \nStates Food and Drug Administration for the treatment of related but different \ndermatologic skin conditions (viz., atopic dermatitis and plaque psoriasis, \nrespectively). The purpose of this review is to summarize the underlying \nbiochemistry and pathophysiology associated with these dermatologic conditions, \nreview the chemistry, pharmacology and safety of each of these products, and \npresent preclinical and clinical evidence that may help explain why these two \nPDE4 inhibitors offer new treatment options for these skin conditions.","PeriodicalId":19875,"journal":{"name":"Pharmacology & Pharmacy","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2018-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"9","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacology & Pharmacy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4236/PP.2018.99028","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 9
Abstract
Two
selective phosphodiesterase-4 (PDE4) inhibitors—viz., crisaborole (Eucrisa®,
Pfizer) and apremilast (Otezla®, Celgene)—have recently received approval by the United
States Food and Drug Administration for the treatment of related but different
dermatologic skin conditions (viz., atopic dermatitis and plaque psoriasis,
respectively). The purpose of this review is to summarize the underlying
biochemistry and pathophysiology associated with these dermatologic conditions,
review the chemistry, pharmacology and safety of each of these products, and
present preclinical and clinical evidence that may help explain why these two
PDE4 inhibitors offer new treatment options for these skin conditions.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
